-
Je něco špatně v tomto záznamu ?
Metabolic interactions of benzodiazepines with oxycodone ex vivo and toxicity depending on usage patterns in an animal model
R. Lawson, P. Čechová, E. Zarrouk, J. Javellaud, V. Bazgier, M. Otyepka, P. Trouillas, N. Picard, P. Marquet, F. Saint-Marcoux, S. El Balkhi
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1968 do Před 1 rokem
Europe PubMed Central
od 1968 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2002-01-01 do Před 1 rokem
Wiley Free Content
od 1997 do Před 1 rokem
PubMed
34855983
DOI
10.1111/bph.15765
Knihovny.cz E-zdroje
- MeSH
- benzodiazepiny toxicita MeSH
- cytochrom P-450 CYP3A MeSH
- diazepam farmakologie MeSH
- lidé MeSH
- modely u zvířat MeSH
- myši MeSH
- opioidní analgetika toxicita MeSH
- oxykodon * MeSH
- oxymorfon MeSH
- předávkování léky * MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND AND PURPOSE: Opioids and benzodiazepines are frequently combined in medical as well as in non-medical contexts. At high doses, such combinations often result in serious health complications attributed to pharmacodynamics interactions. Here, we investigate the contribution of the metabolic interactions between oxycodone, diazepam and diclazepam (a designer benzodiazepine) in abuse/overdose conditions through ex vivo, in vivo and in silico approaches. EXPERIMENTAL APPROACH: A preparation of pooled human liver microsomes was used to study oxycodone metabolism in the presence or absence of diazepam or diclazepam. In mice, diazepam or diclazepam was concomitantly administered with oxycodone to mimic acute intoxication. Diclazepam was introduced on Day 10 in mice continuously infused with oxycodone for 15 days to mimic chronic intoxication. In silico modelling was used to study the molecular interactions of the three drugs with CYP3A4 and 2D6. KEY RESULTS: In mice, in acute conditions, both diazepam and diclazepam inhibited the metabolism of oxycodone. In chronic conditions and at pharmacologically equivalent doses, diclazepam drastically enhanced the production of oxymorphone. In silico, the affinity of benzodiazepines was higher than oxycodone for CYP3A4, inhibiting oxycodone metabolism through CYP3A4. Oxycodone metabolism is likely to be diverted towards CYP2D6. CONCLUSION AND IMPLICATIONS: Acute doses of diazepam or diclazepam result in the accumulation of oxycodone, whereas chronic administration induces the accumulation of oxymorphone, the toxic metabolite. This suggests that overdoses of opioids in the presence of benzodiazepines are partly due to metabolic interactions, which in turn explain the patterns of toxicity dependent on usage. LINKED ARTICLES: This article is part of a themed issue on Advances in Opioid Pharmacology at the Time of the Opioid Epidemic. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.7/issuetoc.
Department of Pharmacology Toxicology and Pharmacovigilance CHU Limoges Limoges France
Department of Physical Chemistry Faculty of Science Palacký University Olomouc Olomouc Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003732
- 003
- CZ-PrNML
- 005
- 20230425140837.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bph.15765 $2 doi
- 035 __
- $a (PubMed)34855983
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lawson, Roland $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France $1 https://orcid.org/0000000206848809
- 245 10
- $a Metabolic interactions of benzodiazepines with oxycodone ex vivo and toxicity depending on usage patterns in an animal model / $c R. Lawson, P. Čechová, E. Zarrouk, J. Javellaud, V. Bazgier, M. Otyepka, P. Trouillas, N. Picard, P. Marquet, F. Saint-Marcoux, S. El Balkhi
- 520 9_
- $a BACKGROUND AND PURPOSE: Opioids and benzodiazepines are frequently combined in medical as well as in non-medical contexts. At high doses, such combinations often result in serious health complications attributed to pharmacodynamics interactions. Here, we investigate the contribution of the metabolic interactions between oxycodone, diazepam and diclazepam (a designer benzodiazepine) in abuse/overdose conditions through ex vivo, in vivo and in silico approaches. EXPERIMENTAL APPROACH: A preparation of pooled human liver microsomes was used to study oxycodone metabolism in the presence or absence of diazepam or diclazepam. In mice, diazepam or diclazepam was concomitantly administered with oxycodone to mimic acute intoxication. Diclazepam was introduced on Day 10 in mice continuously infused with oxycodone for 15 days to mimic chronic intoxication. In silico modelling was used to study the molecular interactions of the three drugs with CYP3A4 and 2D6. KEY RESULTS: In mice, in acute conditions, both diazepam and diclazepam inhibited the metabolism of oxycodone. In chronic conditions and at pharmacologically equivalent doses, diclazepam drastically enhanced the production of oxymorphone. In silico, the affinity of benzodiazepines was higher than oxycodone for CYP3A4, inhibiting oxycodone metabolism through CYP3A4. Oxycodone metabolism is likely to be diverted towards CYP2D6. CONCLUSION AND IMPLICATIONS: Acute doses of diazepam or diclazepam result in the accumulation of oxycodone, whereas chronic administration induces the accumulation of oxymorphone, the toxic metabolite. This suggests that overdoses of opioids in the presence of benzodiazepines are partly due to metabolic interactions, which in turn explain the patterns of toxicity dependent on usage. LINKED ARTICLES: This article is part of a themed issue on Advances in Opioid Pharmacology at the Time of the Opioid Epidemic. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.7/issuetoc.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 12
- $a oxykodon $7 D010098
- 650 _2
- $a oxymorfon $7 D010111
- 650 _2
- $a cytochrom P-450 CYP3A $7 D051544
- 650 _2
- $a benzodiazepiny $x toxicita $7 D001569
- 650 _2
- $a diazepam $x farmakologie $7 D003975
- 650 _2
- $a opioidní analgetika $x toxicita $7 D000701
- 650 _2
- $a modely u zvířat $7 D023421
- 650 12
- $a předávkování léky $7 D062787
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Čechová, Petra $u Regional Center of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute (CATRIN), Palacký University Olomouc, Olomouc, Czechia $1 https://orcid.org/0000000250696398
- 700 1_
- $a Zarrouk, Eliès $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France
- 700 1_
- $a Javellaud, James $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France
- 700 1_
- $a Bazgier, Václav $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, Olomouc, Czechia
- 700 1_
- $a Otyepka, Michal $u Regional Center of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute (CATRIN), Palacký University Olomouc, Olomouc, Czechia
- 700 1_
- $a Trouillas, Patrick $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France $u Regional Center of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute (CATRIN), Palacký University Olomouc, Olomouc, Czechia
- 700 1_
- $a Picard, Nicolas $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France $u Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France
- 700 1_
- $a Marquet, Pierre $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France $u Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France
- 700 1_
- $a Saint-Marcoux, Franck $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France $u Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France
- 700 1_
- $a El Balkhi, Souleiman $u INSERM, IPPRITT, U1248, Limoges, France $u Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France $1 https://orcid.org/0000000297435603
- 773 0_
- $w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 180, č. 7 (2023), s. 829-842
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34855983 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425140833 $b ABA008
- 999 __
- $a ok $b bmc $g 1924420 $s 1189941
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 180 $c 7 $d 829-842 $e 20220122 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
- LZP __
- $a Pubmed-20230418